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Abstract
Human metapneumovirus (HMPV) encodes a small hydrophobic (SH) protein of unknown function. HMPV from which the
SH open reading frame was deleted (HMPVDSH) was viable and displayed similar replication kinetics, cytopathic effect and
plaque size compared with wild type HMPV in several cell-lines. In addition, no differences were observed in infection
efficiency or cell-to-cell spreading in human primary bronchial epithelial cells (HPBEC) cultured at an air-liquid interphase.
Host gene expression was analyzed in A549 cells infected with HMPV or HMPVDSH using microarrays and mass
spectrometry (MS) based techniques at multiple time points post infection. Only minor differences were observed in mRNA
or protein expression levels. A possible function of HMPV SH as apoptosis blocker, as proposed for several members of the
family Paramyxoviridae, was rejected based on this analysis. So far, a clear phenotype of HMPV SH deletion mutants in vitro
at the virus and host levels is absent.
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Introduction
Since its discovery in 2001, the epidemiology, prevalence, and
clinical signs of human metapneumovirus (HMPV) have been
studied extensively [1,2,3,4,5]. Based on genetic and antigenic
analyses, four sublineages of HMPV (A1, A2, B1 and B2) have
been identified [1,6]. Reverse genetics systems are now available
for all four sublineages facilitating fundamental and applied
research [7,8].
The non-segmented negative sense genome of HMPV encodes
at least 9 putative open reading frames (ORFs); from the 3’ to 5’
ends: nucleoprotein (N), phosphoprotein (P), matrix protein (M),
fusion protein (F), M2-1 and M2-2, small hydrophobic protein
(SH), attachment protein (G), and large polymerase protein (L) [9].
For most of these ORFs a possible function has been assigned
based on homologies of closely related viruses such as the human
respiratory syncytial virus (HRSV). However, several studies have
demonstrated that there are functional differences between the
ORFs of HRSV and HMPV. For example, HRSV M2.1 was
described as a transcriptional elongation factor that is required for
virus viability [10], while recombinant HMPV can be recovered in
the absence of M2.1 Furthermore HMPV M2.1 deletion mutants
replicated efficiently in vitro but not in vivo [7,11]. Similarly, in
contrast to the HRSV G protein, the HMPV G protein is not
essential for replication in vivo [12,13].
The enveloped HMPV particles potentially contain three virus
encoded transmembrane glycoproteins, the F, G and SH proteins.
A function for the SH protein cannot readably be assigned for
HMPV since its function is largely unclear for other members of
the genus Pneumovirinae. The SH protein of mumps virus (MuV) is a
type I transmembrane protein, whereas the SH proteins of other
paramyxoviruses are type II transmembrane proteins. The HMPV
SH protein was found to be expressed in several different forms in
virus infected cells depending on the glycosylation status: an
unglycosylated form (SH0), an N-glycosylated form (SHg1) and a
more extensively glycosylated form (SHg2) [12,14]. The SH
protein of HMPV is the largest among the members of the family
Paramyxoviridae, 183 aa for HMPV-A and 177 aa for HMPV-B
compared to avian metapneumovirus subgroup A (AMPV-A) (81
aa), AMPV-B (175 aa), AMPV-C (177 aa), HRSV (64 aa), bovine
respiratory syncytial virus (BRSV) (81 aa), MuV (57 aa) and
parainfluenza virus type 5 (PIV5) (44 aa). Sequence similarity
between HMPV and AMPV-C was found to be low and there is
no discernable sequence identity with the SH proteins of other
viruses [9,15].
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HRSV from which SH was deleted was previously found to
replicate efficiently in cell culture and slightly less efficient in the
higher upper respiratory tract of mice and in the lower respiratory
tract of chimpanzees [16,17]. In contrast, HMPV SH deletion
mutants replicated with an efficiency similar to that of wild type
HMPV in the upper and lower respiratory tract of hamsters [12]
and replicated only marginally less efficient in non-human
primates [18]. The SH proteins of members of the family
Paramyxoviridae have been suggested to act as a viroporin [19,20],
or to have a function in blocking the TNF-a-mediated apoptosis
pathway [14,21,22,23]. PIV5 from which the SH was deleted
(PIV5DSH) was viable and displayed similar replication kinetics
and plaque size compared to the wild type virus, but caused
increased cytopathic effect (CPE) in MDBK and L929 cells, via
TNF-a-mediated apoptosis [23,24].
To study the function of the SH protein of HMPV, SH deletion
mutants were generated using a wild type HMPV or HMPV
encoding green fluorescent protein (GFP) as backbone [25]. These
deletion mutants replicated with similar efficiency as the parental
viruses in Vero-118 cells and human primary bronchial epithelial
cells (HPBEC) cultured at air-liquid interphase. Only minor
differences were observed in host gene or protein expression levels
using microarrays and mass spectrometry (MS) based methods
upon infection of the A549 lung fibroblast cell line with HMPV or
HMPV SH deletion mutants. Based on this study it was concluded
that the SH protein of HMPV has no identifiable function in the
context of the virus and host cells in vitro.
Results
Replication characteristics of HMPV SH deletion mutants
in tissue culture
To investigate the function of the HMPV SH protein, SH
deletion mutants were generated by removing the SH ORF,
resulting in HMPVDSH. A similar deletion mutant was generated
using a recombinant HMPV expressing GFP as backbone virus,
resulting in HMPVDSH-GFP. Replication curves were generated
to compare the replication kinetics of HMPV SH deletion mutants
with those of parental HMPV (Figure 1). There were no apparent
differences in replication kinetics between wild type HMPV and
HMPVDSH confirming that the SH protein is dispensable in-vitro
in Vero-118 cells. Moreover, HMPV-GFP and HMPVDSH-GFP
replicated to similar titers as wild type HMPV as well. For RSV,
the deletion of SH did not alter the replication kinetics or
production of syncytia but did result in plaques which were 70%
larger than plaques produced by wild type RSV [17]. To
investigate the impact of the HMPV SH deletion on CPE,
Vero-118 cells infected with HMPV and HMPVDSH were
photographed five days after inoculation (Figure 2, left panels).
CPE was indistinguishable between HMPV and HMPVDSH
infected Vero-118 cells; both viruses yielded focal rounding and
detachment of cells and no syncytium formation. Plaque assays
performed with Vero-118 cells inoculated with HMPV or
HMPVDSH and overlaid with methylcellulose revealed that
plaque sizes were similar (Figure 2, right panels).
Analysis of SH expression
Expression of the SH protein in HMPV-infected cells and
virions was analyzed by Western blot (Figure 3). Vero-118 cells
were inoculated with HMPV or HMPVDSH and cells and the
supernatant were harvested 7 days post inoculation (p.i.). Virus-
particle-containing supernatant was subsequently concentrated
and purified on sucrose gradients. 293T cells transfected with a
plasmid expressing the SH protein (pCAGGS-SH) served as a
positive control for SH expression. Two additional bands were
observed for samples containing the SH protein: 293T cells
transfected with pCAGGS-SH (lane 2), cells infected with HMPV
(lane 4) and purified HMPV virions (lane 6). These bands of 19
Figure 1. Replication kinetics of HMPV and SH deletion
mutants. Vero-118 cells were inoculated at a MOI of 0.1 with HMPV
(closed circle), HMPVDSH (open circle), HMPV-GFP (closed triangle
down) and HMPVDSH-GFP (open triangle down). Supernatants were
collected daily and virus titres were determined by plaque assay.
doi:10.1371/journal.pone.0058572.g001
Figure 2. Cytopathic effect (CPE, left panels) or plaques (right
panels) in mock (a and d), wild type HMPV (b and e) or
HMPVDSH (c and f) inoculated Vero-118 cells. Left panels, Vero-
118 cells were inoculated at a MOI of 0.1 and were subsequently
photographed without further treatment 6 days after inoculation. Right
panels, Vero-118 cells were inoculated and incubated with a
methylcellulose overlay. Plaques were visualized by immunostaining 6
days after inoculation.
doi:10.1371/journal.pone.0058572.g002
Function of HMPV SH Protein
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and 26 kDa were not detected for 293T cells transfected with
PCAGGS (lane 1), cell infected with HMPVDSH (lane 3) and
purified HMPVDSH virions (lane 5). The band of 19 kDa
corresponds to the calculated size (20.1 kDa) of the non-
glycosylated form of the SH protein and is designated SH0. The
other band of 26 kDa (designated SHg1) presumably represents
the N-glycosylated form [12].
In addition to Western blot analysis, the differential expression
of the SH protein for HMPV and HMPVDSH virions was
confirmed by nano Liquid Chromatography (LC) Electrospray
Ionization (ESI) Orbitrap Mass Spectrometry (MS) analysis. To
specifically detect the SH protein, samples were run employing an
inclusion list of 13 theoretical tryptic SH peptides (Table S1). The
peptide VENNLQACQPK of the SH protein was found for the
purified HMPV but not for the purified HMPVDSH virions.
Unlike most of the theoretical tryptic SH peptides, VENNL-
QACQPK does not contain potential glycosylation sites. The
peptide was found with a Mascot ion score of 42 with a significant
threshold of p,0.01 and zero modifications, confirming the
expression of the SH protein.
Replication characteristics of HMPV and HMPVDSH in
HPBEC
HMPV is known to replicate primarily in ciliated respiratory
epithelial cells in macaques [26]. Therefore we next investigated
the phenotype of HMPV and HMPVDSH in air-liquid interphase
cultures of HPBEC, as these cultures have a pseudo stratified
epithelial phenotype and consist of both ciliated and mucus
producing cells, similar to airway epithelium in vivo [27]. Cells were
pre-treated with lysophosphatidylcholine (LPC) to enhance infec-
tion efficiency, and inoculated with HMPV or HMPVDSH. Every
day, fresh medium containing trypsin was added and mucus
overlays were washed. HMPV and HMPVDSH both replicated in
HPBEC but no differences were observed in virus spread or the
number of virus infected cells between the two viruses (Figure 4a
and c). A separate staining specific for ciliated cells was performed,
revealing that primarily ciliated cells were infected with HMPV
(Figure 4b and d).
MRNA profiling of HMPV- and HMPVDSH-infected A549
cells
Messenger RNA profiling was performed to identify and
characterize differences in the host response to HMPV and
HMPVDSH infection. To this end, A549 cells inoculated with
HMPV, HMPVDSH or medium were harvested 6, 12, 24 and 36
hours p.i. for microarray analysis using Affymetrix HG-U133 plus
2.0 GeneChips. Differentially expressed host genes between
HMPV, HMPVDSH and mock infected cells were identified
using limma analysis. The analysis revealed that 523 out of the
19,006 genes that were studied were differentially expressed in at
least one of the three pairwise comparisons, at any time point,
when applying a false discovery rate (FDR) of smaller or equal to
0.05 and a 2log fold change threshold of 1 (equals an absolute fold
change of 2). Increasing over time, HMPV and HMPVDSH
infections both affected the gene expression level of more than 300
genes (Table 1). Pathway analysis revealed that the function of
these differentially expressed genes was most significantly associ-
ated with (innate) biological processes like apoptosis, immune cell
trafficking, cell-to-cell signaling and cell-cell interactions. The
results were remarkably similar to results found for wild type
HMPV infection by Bao et al (30). The fold change of these up- or
down regulated genes, relative to base line expression levels as
measured in mock infected cells, ranged up to 7 (equals an
absolute fold change of 128, Table 2 and 3). Figure 5 shows that
HMPV and HMPVDSH infections change the expression level of
a similar set of genes in a very similar fashion. Limma analysis of
the genome wide expression profiles indeed revealed that only 35
genes were significantly differentially regulated when comparing
the HMPV and HMPVDSH infections directly (Table 1, 2 and 3).
Pathway analysis revealed that these genes were associated with
extravasation, recruitment, adhesion and infiltration of cells of
lymphoid origin, apoptosis, cell activation and differentiation, and
interferon signaling.
Figure 3. Western blot analysis of the SH protein. 293T cells
transfected with pCAGGS (lane 1), pCAGGS-SH (lane 2), Vero-118 cells
infected with HMPV (lane 3) or HMPV DSH (lanes 4) and purified virions
of HMPVDSH (lane 5) and HMPV (lane 6) were analyzed on 12.5%
polyacryamide gels. The SH protein was detected using rabbit serum
raised against a mixture of petides representing aa 2–16 and 95–110 of
the SH protein.
doi:10.1371/journal.pone.0058572.g003
Figure 4. HPBEC cultured at air-liquid interphase were
inoculated with wild type HMPV (a, b and d) or HMPVDSH (c)
at a MOI of 4. Six days after inoculation, infected cells were visualized
by immunostaining with HMPV specific polyclonal anti-serum (a and c).
The HMPV-infected cells from panel b and d are the same field of cells,
double stained for HMPV infected cells (b) and ciliated cells by staining
with anti ß-tubulin antibodies (d).
doi:10.1371/journal.pone.0058572.g004
Function of HMPV SH Protein
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Table 1. Number of up- and down-regulated genes in pairwise comparisons following inoculation of A549 cells with HMPV,
HMPVDSH or mock inoculated A549 cells at 6, 12, 24 and 36 hours.
Up-regluated* Down-regulated*
hours p.i. HMPV vs HMPVDSH HMPV vs mock HMPVDSH vs mock HMPV vs HMPVDSH HMPV vs mock HMPVDSH vs mock
6 20 73 14 0 0 0
12 5 185 215 12 5 1
24 0 195 188 0 16 15
36 1 328 315 1 61 51
*Applying a 2log fold change of 1 and a FDR ,= 0.05.
doi:10.1371/journal.pone.0058572.t001
Table 2. Up-regulated genes (FDR ,= 0.05) with a minimum fold change of 1 (2log values) in A549 cells infected with HMPV
compared with HMPVDSH infected cells (column 3).
Symbol Gene name HMPV vs HMPVDSH HMPV vs mock HMPVDSH vs mock hours p.i.
TCHH trichohyalin 1.59 2.07 n.s.* 6
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma
growth stimulating activity, alpha)
1.56 3.12 1.56 6
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 3
1.45 2.64 1.20 6
STAT5A signal transducer and activator of
transcription 5A
1.35 1.78 n.s. 6
ARL14 ADP-ribosylation factor-like 14 1.33 1.33 n.s. 6
MMP10 matrix metallopeptidase 10 (stromelysin 2) 1.33 1.46 n.s. 6
MX1 myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
1.25 2.64 1.39 6
GBP1 guanylate binding protein 1,
interferon-inducible, 67kDa
1.23 2.13 0.90 6
CCL5 chemokine (C-C motif) ligand 5 1.23 2.01 0.78 6
LAMB3 laminin, beta 3 1.21 1.36 n.s. 6
IFIT3 interferon-induced protein with
tetratricopeptide repeats 3
1.20 3.13 1.94 6
CMPK2 cytidine monophosphate (UMP-CMP)
kinase 2, mitochondrial
1.13 2.38 1.24 6
SELE selectin E 1.11 1.26 n.s. 6
ICAM1 intercellular adhesion molecule 1 1.11 1.95 0.84 6
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 1.08 1.67 n.s. 6
IRF1 interferon regulatory factor 1 1.02 1.55 n.s. 6
IL1A interleukin 1, alpha 1.02 2.66 1.65 6
MRGPRX3 MAS-related GPR, member X3 1.02 1.60 0.58 6
ZC3H12A zinc finger CCCH-type containing 12A 1.01 1.88 0.87 6
PLAT plasminogen activator, tissue 1.01 1.27 n.s. 6
MMP10 matrix metallopeptidase 10 (stromelysin 2) 2.04 2.25 n.s. 12
MMP1 matrix metallopeptidase 1
(interstitial collagenase)
1.79 1.39 n.s. 12
STC1 stanniocalcin 1 1.50 1.87 n.s. 12
ANPEP alanyl (membrane) aminopeptidase 1.35 1.04 n.s. 12
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 3
1.29 2.66 1.37 12
LCN2 lipocalin 2 1.08 2.31 1.24 36
The relative fold change for these genes when comparing HMPV and HMPVDSH infections with mock infected cells is provided in column 4 and 5.
*not significantly differentially regulated.
doi:10.1371/journal.pone.0058572.t002
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Differences in host gene expression between HMPV- and
HMPVDSH-infected cells were almost exclusively (33 out of 35
genes) observed at early timepoints (6 and 12 hours p.i.), and
differences in gene expression levels were relatively low (up to 3,
2log values). Moreover, the upregulation or downregulation of
these genes is similar for both HMPV- and HMPVDSH-infected
cells compared to mock-infected cells. Only due to small
differences in timing of these responses, these genes were found
to be differentially expressed. Taken together, HMPV infection
induced a profound perturbation of mRNA expression levels, but
the mRNA expression profiles of HMPV and HMPVDSH were
remarkably similar if not identical, thus the expression of the
HMPV SH protein during infection does not have an effect on
host gene expression.
Peptide profiling of HMPV and HMPVDSH infected A549
cells
Samples of A549 cells inoculated with HMPV and HMPVDSH
that were used for the microarray analysis were also analyzed
using Matrix-assisted laser desorption/ionisation (MALDI) Fourier
Transform Ion Cyclotron Resonance Mass Spectrometer (FT-MS)
and LC MALDI Time-of-Flight (TOF)/TOF. For peptide
profiling, samples collected at 12, 24 and 36 hours p.i. were
analyzed. When applying a signal to noise ratio of 10,
approximately 800 mass peaks could be identified in a typical
A549 derived peptide profile. On average, these peaks relate to
500 peptides originating from about 400 distinct proteins. When
comparing peptide profiles of HMPV infected cells with mock
infected cells obtained at the same time point, up to 100 mass
peaks differing in signal intensity were observed. In addition to
host peptides that were differentially expressed upon infection,
several peptides specific for the HMPV N, P and M2.1 proteins
were detected at 12, 24 and 36 p.i. in the HMPV and HMPVDSH
infected cells but not in the mock infected cells (data not shown).
The HMPV SH protein was not detected, which could be due to
low expression levels, the relatively small size of the protein or
glycosylation status. When comparing the peptide profiles derived
from HMPV and HMPVDSH inoculated cells directly, not a
single host derived peptide was differentially expressed. Thus, no
effect of the HMPV SH protein on protein expression profiles in
infected A549 cells was detected.
Discussion
Despite years of research, little is known about the function of
the SH protein of members of the subfamily Pneumovirinae. For
HRSV the SH protein can be deleted with minimal effect on virus
replication in vitro [12,17,28]. HMPV SH deletion mutants
replicated as efficient as wild type HMPV in Vero-118 cells and
did not display differences in CPE and plaque size. This is in
agreement with the results described for HMPV by others using
LLC-MK2 cells [12]. Replication curves of HMPV and
HMPVDSH in cell lines such as MDBK, 293T and A549 cells
also did not reveal any differences in replication kinetics or CPE
(data not shown). HMPV is known to replicate primarily in ciliated
respiratory epithelial cells in macaques [26]. For that reason
HPBEC might represent a more suitable in vitro cell culture model.
HPBEC cultures consist of polarized cells with a pseudostratified
mucociliary histology that is very similar to bronchial epithelium in
vivo. HPBEC cultures are derived from lung tissue samples and
contain a wide variety of cells, including mucus producing cells
and ciliated cells. Similar to RSV [29], both HMPV and
HMPVDSH were primarily detected in ciliated cells. No
differences were observed in cell-to-cell spread, the number of
virus infected cells or CPE in these cell cultures.
The deletion of the SH protein of PIV5 resulted in an increase
of CPE and apoptosis in several cell lines, such as A549, MDBK,
HeLaT4 and L929 [24]. The PIV5 SH protein was shown to
block the TNF-a-mediated apoptosis in L929 cells. Assays with
chimeric PIV5DSH expressing the SH proteins of other viruses
revealed that the MuV and RSV SH proteins have a similar
Table 3. Down-regulated genes (FDR ,= 0.05) with a minimum fold change of 1 (2log values) in A549 cells infected with HMPV
compared with HMPVDSH infected cells (column 3).
symbol Gene name HMPV vs HMPVDSH HMPV vs mock HMPVDSH vs mock hours p.i.
IL28A interleukin 28A (interferon, lambda 2) –1.762 2.633 4.395 12
IDO1 indoleamine 2,3-dioxygenase 1 –1.65 1.374 3.024 12
NA NA –1.308 –1.658 n.s.* 12
TNFSF10 tumor necrosis factor (ligand) superfamily,
member 10
–1.305 2.125 3.43 12
IL29 interleukin 29 (interferon, lambda 1) –1.3 1.804 3.104 12
LAMP3 lysosomal-associated membrane protein 3 –1.219 2.007 3.226 12
IFNB1 interferon, beta 1, fibroblast –1.188 2.29 3.478 12
PKDCC protein kinase domain containing,
cytoplasmic homolog
–1.109 n.s. 1.098 12
NA NA –1.1 –1.049 n.s. 12
RARRES3 retinoic acid receptor responder
(tazarotene induced) 3
–1.1 0.866 1.966 12
TNFSF13B tumor necrosis factor (ligand)
superfamily, member 13b
–1.057 2.072 3.129 12
NA NA –1.04 –0.523 0.517 12
APOL6 apolipoprotein L, 6 –1.653 n.s. 2.114 36
The relative fold change for these genes when comparing HMPV and the HMPVDSH infections with mock infected cells is provided in column 4 and 5.
*not significantly differentially regulated.
doi:10.1371/journal.pone.0058572.t003
Function of HMPV SH Protein
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e58572
function in blocking the TNF-a-induced NF-kB activation
[21,22]. Infection of Vero-118 with PIV5DSH resulted in a major
increase in CPE compared to PIV5 (data not shown). In contrast
Vero-118 or A549 cells infected with HMPV and HMPVDSH did
not display this phenotype. Thus, the deletion of HMPV SH does
not result in a similar change of phenotype as the deletion of PIV5
SH in vitro.
RNA microarray analysis of A549 cells infected with HMPV or
HMPVDSH revealed that more than 500 genes were differentially
expressed over time (cumulative count). Similar results have been
obtained by Bao et al [30]. HMPV infection altered the
transcriptome network considerably but direct comparison of
HMPV and HMPVDSH infections revealed only marginal
differences between the genome wide expression profiles. Further-
more, the differences were restricted to the first 12 hours of
infection and mainly involved innate immunity genes that are
induced by both HMPV and HMPVDSH infections when
compared to mock-infected cells. Since the early and transient
gene expression differences are not followed by gene expression
differences at later time points when the expression level of many
genes change, we concluded that the SH protein is transcription-
ally inert and does not affect the in vitro host response phenotype.
Other groups have described reduced interleukin 6 (IL-6) and IL-8
expression in A549 cells infected with HMPV compared to
HMPVDSH, although this difference was only found at 3 and 6 h
p.i., and disappeared at 15 h p.i. [14]. It was hypothesised that the
down regulation of IL-6 and IL-8 was a result of the inhibition of
NF-kB dependent transcription by the SH protein, since NF-kB is
required for IL-8 and IL-6 expression, thereby suggesting a
possible role of the SH protein in blocking of apoptosis [31,32].
However, microarray analysis of HMPV and HMPVDSH infected
A549 infected cells did not reveal differential expression of genes
encoding IL-6 and IL-8 or other genes involved in the apoptosis
pathways, thereby refuting a possible role of HMPV SH in TNF-
a-induced NF-kB activation.
Expression levels of mRNA are not always consistent with
protein levels and post-translational protein modifications may be
altered in virus infected cells [33]. Therefore, protein expression
profiles of HMPV and HMPVDSH infected A549 cells were
generated. Approximately 100 peptides were found to be
differentially expressed between HMPV and mock infected cells,
some of which represented viral proteins. However, there were no
differences in protein expression profiles between HMPV and
HMPVDSH infected A549 cells.
From these results, we conclude that the function of SH is still
not clear. Since HMPV displays a high mutation rate and because
Figure 5. Heat map displaying differential expression of genes of A549 cells following inoculation with wild type HMPV, HMPVDSH
or mock 6, 12, 24, or 36 hours in duplicate (Induced blue, repressed red values).
doi:10.1371/journal.pone.0058572.g005
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SH is present in all primary virus isolates, it seems unlikely that SH
has no function in vivo. Frequent frameshift and point mutations in
the SH gene have been observed in in vitro studies by some groups
[34]. This phenomenon may be cell type specific, since repeated
passage of HMPV-B1 viruses in Vero-118 cells did not result in
mutations in the SH ORF [35]. This is suggestive of lack of SH
function in in vitro models. HMPV SH deletion mutants were not
attenuated in hamsters and only slightly attenuated in chimpan-
zees compared to wild type HMPV [12,14,18]. Inoculation of
mice with HMPV SH deletion mutants resulted in enhanced
secretion of proinflammatory mediators compared with wild type
HMPV, although both viruses replicated to similar titers [14]. The
lack of a clear phenotype could be due to the fact that the animal
models used do not mimic the human physiology sufficiently to
read out a possible phenotype for the HMPV SH deletion
mutants. Therefore, future studies on SH function of metapneu-
moviruses should focus on the natural hosts, birds and humans for
AMPV and HMPV respectively. From the studies conducted so
far, we conclude that the function of the HMPV SH protein is yet
to be discovered.
Methods
Cells and media
Vero-118 cells [26] were cultured in Iscove’s Modified
Dulbecco’s medium (IMDM, BioWhittaker, Verviers, Belgium)
supplemented with 10 % Fetal Calf serum (FCS), 100 IU of
penicillin ml-1, 100 mg of streptomycin ml-1, and 2 mM glutamine
as described previously [7]. 293T cells were grown in Dulbecco’s
modified eagle medium (DMEM, BioWhittaker, Verviers, Bel-
gium), supplemented with 10% FCS, nonessential amino acids,
100 IU of penicillin/ml, 100 mg of streptomycin/ml and 2 mM
glutamine. Baby hamster kidney cells stably expressing T7 RNA
polymerase (BSR-T7), a kind gift of Dr K. Conzelmann, [36] were
grown in DMEM supplemented with 10 % FCS, nonessential
amino acids, 100 IU of Penicillin ml-1, 100 mg of streptomycin ml-
1, 2 mM glutamine and 0.5 mg ml-1 of G418 (Invitrogen, Breda,
The Netherlands). For HMPV rescue, Vero-118 cells and BSR-T7
cells were co-cultured in DMEM supplemented with 3 % FCS,
100 IU of penicillin ml-1, 100 mg of streptomycin ml-1, 2 mM
glutamine, and 0.25 mg trypsin ml-1. For virus propagation and
titration, Vero-118 cells were grown in IMDM supplemented with
4 % bovine serum albumin fraction V (Invitrogen, Breda), 100 IU
of penicillin, 2 mM glutamine, and 3.75 mg of trypsin ml-1. A549
cells were cultured in HAM F12 medium containing 100 IU of
penicillin ml-1, 100 mg of streptomycin ml-1, 2 mM glutamine and
10 % FCS (Hyclone, Logan, USA). For virus infection, A549 were
grown in HAM F12 medium containing 100 IU of penicillin ml-1,
100 mg of streptomycin ml-1, 2 mM glutamine and 4 % bovine
serum albumin fraction V (Invitrogen).
Subcultures of HPBEC were obtained from resected lung tissue
as previously described [27]. Briefly, HPBEC were grown in
keratinocyte serum-free medium (KSFM, Invitrogen) supplement-
ed with 0.2 ng/ml epithelial growth factor (Invitrogen), 25 mg/ml
bovine pituitary extract (Invitrogen), 1 mM isoproterenol, 20 U/
ml penicillin and 20 mg/ml streptomycin. For air-liquid inferphase
cultures, cells were seeded (1.56105 cells/cm2) in DMEM/
bronchial epithelial cell medium (BEGM) 1 1 medium with
supplements (Bulletkit; Lonza, Breda, The Netherlands) on 24-well
transwell inserts (0.4 mm pore-size, 6 mm diameter; Corning
Incorporated, Schiphol-Rijk, The Netherlands) that were pre-
coated with 10 mg/ml bovine fibronectin (Sigma, Zwijndrecht,
The Netherlands), 30 mg/ml Purecol (Inamed, Fremont, CA), and
10 mg/ml bovine serum albumin in PBS. When cell layers were
confluent the apical medium was removed and basal medium was
replaced with DMEM/BEGM medium supplemented with
10 nM retinoic acid (Sigma, Zwijndrecht, The Netherlands). Cells
were allowed to differentiate for 2 weeks.
Differentiated air-liquid interphase cultures were pretreated
with LPC prior to inoculation with HMPV. Basal medium of air-
liquid interphase cultures was replaced with HBS (150 mM NaCl,
20 mM HEPES pH 7.5, 1 mM MgCl2 and 1 mM CaCl2) and the
apical side washed 3x with HBS with 75 ug/ml LPC for 10 min.
Basal HBS was then replaced with DMEM/BEGM medium and
HMPV was added. Six days after inoculation a double staining
was performed, infected cells were visualized by immunostaining
with HMPV specific polyclonal anti-serum and ciliated cells were
detected by staining with anti ß-tubulin antibodies.
Full-length cDNA vectors
The full-length cDNA plasmids for HMPV-B1 (NL/1/99) and
HMPV-B1 expressing the green fluorescent protein (HMPV-GFP)
have been described previously [7,25]. For the construction of the
full-length HMPV-B1 cDNA plasmids lacking the SH ORF,
fragments of HMPV-B1 spanning the gene start (GS) of SH or the
gene end (GE) of SH were amplified by PCR by primers flanked
by type II restriction sites, and cloned into pBluescript SK+. Using
the type II restriction sites, fragments were cloned such that the
GS of SH, was directly ligated to the GE of SH, thus omitting the
SH ORF. Using unique restriction sites, the fragment lacking the
SH ORF was swapped back into the full-length HMPV-B1 cDNA
plasmids resulting in HMPVDSH and HMPVDSH-GFP. All
plasmids were sequenced to ensure the absence of undesired
mutations. All primer sequences are available upon request.
Recovery of recombinant virus
Recombinant HMPV was generated as described previously
[7]. Briefly, BSR-T7 cells were co-transfected for 5 hours with
5 mg of the full-length HMPV cDNA plasmid, 2 mg pCITE-N,
2 mg pCITE-P, 1 mg pCITE-L and 1 mg pCITE-M2.1 using
Lipofectamine 2000 (Invitrogen). After transfection, the media was
replaced with fresh media supplemented with trypsin. Three days
after transfection, the BSR-T7 cells were scraped and cocultured
with Vero-118 cells for 8 days. After one freeze–thaw cycle, cell-
free supernatants were purified and concentrated using a 20–60%
(w/w) sucrose gradient. Viral RNA was isolated after recovery of
the virus and sequenced to ensure no point mutations or frame
shifts had occurred in the SH ORF.
Virus titrations
Viruses were propagated in Vero-118 cells and virus titers were
determined as described previously [7]. Briefly, confluent mono-
layers of Vero-118 cells in 96-well plates were spin-inoculated (15
min., 2000 x g) with 100 ml of ten fold serial dilutions of each
sample and incubated at 37uC. After 2 hours and again after 3-4
days, the inoculum was replaced with fresh infection media. Seven
days after inoculation, infected wells were identified by immuno-
fluorescence assays with HMPV-specific polyclonal antiserum
raised in guinea pigs, as described previously [1]. Titers expressed
as 50 % tissue culture infectious dose (TCID50) were calculated as
described by Reed and Muench [37].
Replication curves
Replication curves were generated as described previously [7].
Twenty-five cm2 flasks containing confluent Vero-118 cells were
inoculated for 2 h at 37uC with HMPV, HMPV-GFP,
HMPVDSH or HMPVDSH-GFP at a multiplicity of infection
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(MOI) of 0.1. After adsorption of the virus to the cells, the
inoculum was removed and cells were washed two times with
medium before addition of 7 ml of fresh medium and incubation
at 37uC. Every day, 0.5 ml of supernatant was collected and
replaced by fresh media. Plaque assays were performed to
determine viral titers [7].
Protein electrophoresis and Western blot assay
239T cells were transfected with pCAGGS or pCAGGS
expressing the HMPV-B1 SH protein (pCAGGS-SH, a kind gift
of Dr L. Martı´nez-Sobrido) using the CaPO4 precipitation method
and harvested 48 h after transfection [38]. Vero-118 cells were
infected with HMPV or HMPVDSH and cells were subsequently
harvested 7 days after infection, followed by virus purification on a
60-20% sucrose gradient (2 h, 27000 rpm). All samples were lysed
in hot lysis buffer (1% sodium dodecyl sulfate (SDS]), 100 mM
NaCl, 10 mM EDTA, 10 mM Tris-HCl at pH 7.5), treated with
3X dissociation loading buffer (2% SDS, 0.01 dithiothreitol,
0.02 M Tris-HCl at pH 6.8) for 5 min at 96uC, and analyzed on a
12.5 % SDS-polyacrylamide gels. Proteins were electrotransferred
onto nitrocellulose membranes. The blots were incubated over-
night at 4uC in blocking buffer (PBS with 5% nonfat dried milk
and 0.05% Tween) and subsequently incubated with a 1 200
dilution of rabbit antisera (rabbit anti-SH NL/1/99 raised against
a mixture of peptides representing aa 2 to 16 and 95 to 110 of SH)
in blocking buffer for 2 h at room temperature. Blots were washed
with PBS containing 0.05% Tween and incubated for 1 h with
swine anti-rabbit horseradish peroxidase (Dako, Denmark) at a
dilution of 1 3000 in blocking buffer, washed again, and developed
with ECL Western blotting detection reagents (GE Healthcare,
United Kingdom).
Orbitrap MS analysis
After addition of 80% ethanol/water at -20uC the samples were
incubated at room temperature for one hour. Next, the samples
were centrifuged at 10000 g at 4uC and pellets were sonified in
50 ml 0.1% Rapigest for 1 min using the Ultrasonic Disruptor
Sonifier (Brandson Ultrasonic, Danbury, CT) at 70% amplitude at
a maximum temperature of 25uC. The samples were subsequently
reduced and alkylated with 1,4-dithiothreitol and iodoacetamide
and digested overnight using trypsin (Promega, Madison, WI). The
digestion was terminated by adding trifluoracetic acid (TFA,
Biosolve Valkenswaard) to a final concentration of 0.5% (pH,2).
After incubation for 45 min at 37uC the samples were centrifuged
at 14000 g for 40 min and analyzed using Orbitrap MS. Peptide
measurements were carried out on an Ultimate 3000 nano LC
system (Dionex, Germering, Germany) on-line coupled to a hybrid
linear ion trap/Orbitrap MS (LTQ Orbitrap XL; Thermo Fisher
Scientific, Germany). Digests were loaded onto a C18 trap column
(C18 PepMap, 300 mm ID65 mm, 5 mm particle size, 100 A˚ pore
size; Thermo Fisher Scientific, Amsterdam, The Netherlands) and
desalted for 10 minutes using a flow rate of 20 mL/min 0.1%
TFA. Next, the trap column was switched on-line with the
analytical column (PepMap C18, 75 mm ID 6500 mm, 2 mm
particle and 100 A˚ pore size; Thermo Fisher Scientific) and
peptides were eluted with following binary gradient: 3%–25%
solvent B in 120 min and 25%–50% solvent B in further
60 minutes, where solvent A consist of 0.1% formic acid in water
and solvent B consists of 80% acetonitrile (ACN) and 0.08%
formic acid in water. Column flow rate was set to 250 nL/min.
For MS detection a data-independent acquisition method with a
parent mass list of the theoretical tryptic peptides (carbamido-
methylated cysteine and two miscleavages allowed) of SH protein
(Table S1) was used. A high resolution survey scan recording a
window between 400 and 1800 mass-to-charge (m/z) was
performed in the Orbitrap (value of target of automatic gain
control AGC 106, resolution 30,000 at 400 m/z; lock mass was set
to 445.120025 u (protonated (Si(CH3)2O)6)) [39]. Only masses that
corresponded to the parent mass list within a range of 20 ppm
were selected for MS/MS analysis. MS/MS spectra were searched
against the virus subset of the NCBInr database (version
November 5th, 2011, 881,102 virus sequence entries) using Mascot
version 2.3 (Matrix Science, London, U.K.). Search parameters
were specified as follows: (i) taxonomy, virus; (ii) enzyme, trypsin;
(iii) fixed modification, carbamidomethylation of cysteine; (iv)
variable modification, oxidation of methionine. We used a peptide
tolerance of 10 parts per million (ppm) and a fragment tolerance
0.5 Da.
Biological materials for RNA isolation and protein
purification
A549 cells were seeded at 500.000 cells/well in a 6 wells plate
the day before inoculation. These plates were spin-inoculated (15
min., 2000 X g) with HMPV or HMPVDSH and incubated at
37uC. After 2 hours, the inoculum was replaced with fresh
infection media. After 24 hours, cells were stained with HMPV-
specific polyclonal antiserum and analyzed by FACS. For RNA
isolation cells were washed twice with PBS and homogenized in
1 ml TRIzolH reagent (Invitrogen) and stored at -80˚C.
RNA isolation, labeling, Affymetrix microarray
hybridization and data analysis
The TRIzolH homogenates were processed according to the
manufacturer’s instructions (Invitrogen). Total RNA was isolated
and purified using the RNeasy Mini kit (Qiagen, Hilden,
Germany): 250 ml of ethanol was added to the upper aqueous
phase of the processed TRIzol samples and directly transferred to
the RNeasy spin columns for purification. RNA concentrations
and OD 260/280 ratios were measured with the NanoDropH ND-
1000 UV-VIS spectrophotometer (NanoDrop Technologies,
Wilmington, USA). Assessment of total RNA quality and purity
was performed with the RNA 6000 Nano assay on the Agilent
2100 bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
CDNA was synthesized from total RNA using the One-Cycle
Target Labeling kit (Affymetrix, Santa Clara, CA, USA).
Subsequent biotin-labelled cRNA synthesis, purification and
fragmentation were performed according to the manufacturer’s
recommendations. Fragmented biotinylated cRNA was subse-
quently hybridised onto Affymetrix Human Genome U133 Plus
2.0 microarray chips. Image analysis was performed using
GeneChip Operating Software. Microarray Suite software (Affy-
metrix) was used to generate .dat and .cel files. All processing of
data and statistics were performed in Bioconductor version 2.6,
run in R version 2.11.1. The raw intensity values obtained from
the scanner (the CEL files) were preprocessed using the expresso
function of the affy package (version 1.26.1) [40]. In the expresso
function call, parameters were set to use the perfect match (PM)
probe intensities only. Batchwise background correction and
normalization were performed by the variance stabilization and
calibration (VSN) algorithm (package version 3.16.0, ref 21). The
transformed probe values were summarized into one value per
probe set by the median polish method that is part of the robust
multiarray averaging (RMA) method using probe set definitions
provided by Brainarray (http://brainarray.mbni.med.umich.edu/
Brainarray/default.asp) as defined in custom CDF package version
13.0.0. Probe set wise comparisons between the experimental
conditions were performed by linear models of microarray data
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(Limma) (version 3.4.5) [41]. Correction for multiple testing was
achieved by requiring a false discovery rate (FDR) of 0.05,
calculated with the Benjamini-Hochberg procedure [42]. Pathway
analysis was performed using the Interactive Pathway Analysis
(IPA) module from Ingenuity Systems Inc (Redwood City, CA,
USA). Microarray data are available in the ArrayExpress database
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-
1152.
Protein purification
Protein samples were processed as follows. After centrifugation
of the TRIzolH homogenates and removal of the RNA containing
aqueous phase, proteins were isolated from the organic phase.
The, organic phase was washed with acetone (-20uC) and
precipitated by centrifugation at 10.000 x g three times. Next,
100 ml 0.1% w/v RapiGestTM SF reagent (Walters, Milford, MA,
USA), dissolved in 50 mM ammonium bicarbonate, pH 7.0 was
added and sonicated with an Ultrasonic Disruptor SonifierH II
(Branson Ultrasonics, Danbury, Connecticut, USA). Gold grade
trypsin (Promega, Madison, WI, USA) was added to the protein
solution at 0.1 g/L and incubated overnight at 37uC. Next 10 mL
of 500 mM HCl was added (final concentration: 30–50 mM HCl,
pH,2) and incubated for 45 min at 37uC.
Samples were then processed for proteomics-analyses, per-
formed by a combination of two MS techniques. For peptide
quantification MALDI-FT-MS was used, which measures peptide
masses with an accuracy better than 1 ppm, with a dynamic range
of signal intensities of circa 3–4 orders of magnitude. Identification
of the peptides was performed by off-line LC-MALDI-TOF/TOF.
Next, the masses of the identified peptides were linked to the
MALDI-FT-MS peptide signal intensities to enable fold change
analyses of identified proteins [43], as outlined below.
MALDI-FT-MS
MALDI-FT-MS was performed as described previously [44].
Samples were spotted onto a 600/384 AnchorChip target plate
(Bruker Daltonics, Leipzig, Germany) in duplicate. The MALDI-
FTMS measurements were performed on a Bruker Apex Q
instrument with 9.4-tesla magnet (Bruker Daltonics). For each
measurement, 200 scans of 10 shots each were accumulated with
60% laser power. Mass spectra were acquired in the mass range of
800–4000 Da. FTMS spectra were processed with a Gaussian
filter and two zero fillings. A standard peptide calibration mixture
(Bruker Daltonics, Leipzig, Germany) was used for external
calibration. To obtain better mass accuracies, an additional post-
acquisition internal calibration step in DataAnalysis version 3.4,
build 169 software (Bruker Daltonics) was performed. Ubiquitous
actin peptide masses (1198.70545, 1515.74913, 1790.89186,
2215.06990, and 3183.61423 m/z) were used for internal
calibration. Peak intensities were retrieved using a peak finding
algorithm that determines the highest peak intensity within a 3
ppm window at both sides of each m/z value present above a
signal to noise ratio of .4, as described previously [45].
MALDI-TOF/TOF-MS
Trypsin digested samples were run on an Ultimate 3000TM
Nano LC System (Dionex, Sunnyvale, California, USA). One ml of
the sample was loaded onto the monolith trap column (200 mm
inner diameter x 5 cm) with a gradient of eluent A (0.05% TFA in
water) and eluent B (80% ACN, 0.04% TFA in water): 0–5 min,
10% eluent B; 70 min, 50%; 71 min, 90%; 76 min, 90%; 77–100
min, 0% using a flow rate of 1.5 ml/min. Fifteen-second fractions
of the sample were spotted automatically onto a 384 prespotted
AnchorChip plate (Bruker Daltonics) containing a-cyano-4-
hydroxycinnamic acid matrix using a robotic system (Probot
Micro Fraction Collector, Dionex). To each fraction 1 ml of water
was added. Finally, we used a 10 mM (NH)4H2PO4 in 0.1% TFA,
water solution to wash the prespotted plate to remove salts. The
plates were subsequently measured by automated MALDI-TOF/
TOF (Ultraflex, Bruker Daltonik GmbH, Leipzig, Germany) using
WARP-LC software. A file containing the MS and the MS/MS
peak lists was submitted to the MASCOT search engine, version
2.1. (Matrix Science, London, UK) using the MSDB database
(release 09-08-2006) allowing 150 ppm parent mass tolerance, 0.5
Dalton fragment tolerance, and one missed trypsin cleavage site.
Supporting Information
Table S1 Theoretical peptides based on trypsine diges-
tion of the HMPV SH protein.
(DOCX)
Acknowledgments
We would like to thank Leontine van der Wel, Helma Vos, Halima Charif,
Bernadette van den Hoogen and Stefan van Nieuwkoop for excellent
technical assistance, and Roel Bakker, Rene Eijkemans and Henk-Jan van
den Ham for bioinformatics and statistical support, Pieter S. Hiemstra
(Leiden University Medical Center, The Netherlands) for the subcultures of
HPBEC and Luis Martı´nez-Sobrido for providing pCAGGS-SH. This
work was sponsored by MedImmune Vaccines, Inc., framework five grant
‘‘Hammocs’’ from the European Union, the Virgo consortium, an
Innovative Cluster approved by the Netherlands Genomics Initiative
(BSIK 03012), Netherlands.
Author Contributions
Conceived and designed the experiments: MdG ADMEO RAMF ACA.
Performed the experiments: MdG SH JA PCB FZB EJAS. Analyzed the
data: MdG PCB MB ADMEO TL RAMF ACA. Contributed reagents/
materials/analysis tools: JA WvIJ TL BS. Wrote the paper: MdG RAMF
ACA.
References
1. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, et al. (2001) A
newly discovered human pneumovirus isolated from young children with
respiratory tract disease. Nat Med 7: 719–724.
2. van den Hoogen BG, Doornum GJJv, Fockens JC, Cornelissen JJ, Beyer WEP,
et al. (2003) Prevalence and clinical symptoms of human metapneumovirus
infection in hospitalized patients. J Infect Dis 188.
3. Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, et
al. (2004) Human metapneumovirus and lower respiratory tract disease in
otherwise healthy infants and children. N Engl J Med 350: 443–450.
4. Kahn JS (2006) Epidemiology of human metapneumovirus. Clin Microbiol Rev
19: 546–557.
5. Schildgen V, van den Hoogen B, Fouchier R, Tripp RA, Alvarez R, et al. (2011)
Human Metapneumovirus: lessons learned over the first decade. Clin Microbiol
Rev 24: 734–754.
6. van den Hoogen BG, Herfst S, Sprong L, Cane PA, Forleo E, et al. (2004)
Antigenic and genetic variability of human metapneumoviruses. Emerg Infect
Dis 10: 658–666.
7. Herfst S, de Graaf M, Schickli JH, Tang RS, Kaur J, et al. (2004) Recovery of
human metapneumovirus genetic lineages a and B from cloned cDNA. J Virol
78: 8264–8270.
8. Biacchesi S, Skiadopoulos MH, Tran KC, Murphy BR, Collins PL, et al. (2004)
Recovery of human metapneumovirus from cDNA: optimization of growth in
vitro and expression of additional genes. Virology 321: 247–259.
9. van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA (2002)
Analysis of the genomic sequence of a human metapneumovirus. Virology 295:
119–132.
10. Fearns R, Collins PL (1999) Role of the M2-1 transcription antitermination
protein of respiratory syncytial virus in sequential transcription. J Virol 73:
5852–5864.
Function of HMPV SH Protein
PLOS ONE | www.plosone.org 9 March 2013 | Volume 8 | Issue 3 | e58572
11. Buchholz UJ, Biacchesi S, Pham QN, Tran KC, Yang L, et al. (2005) Deletion
of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on
RNA synthesis, attenuation, and immunogenicity. J Virol 79: 6588–6597.
12. Biacchesi S, Skiadopoulos MH, Yang L, Lamirande EW, Tran KC, et al. (2004)
Recombinant human Metapneumovirus lacking the small hydrophobic SH and/
or attachment G glycoprotein: deletion of G yields a promising vaccine
candidate. J Virol 78: 12877–12887.
13. Teng MN, Whitehead SS, Collins PL (2001) Contribution of the respiratory
syncytial virus G glycoprotein and its secreted and membrane-bound forms to
virus replication in vitro and in vivo. Virology 289: 283–296.
14. Bao X, Kolli D, Liu T, Shan Y, Garofalo RP, et al. (2008) Human
metapneumovirus small hydrophobic protein inhibits NF-kappaB transcriptional
activity. J Virol 82: 8224–8229.
15. Yunus AS, Govindarajan D, Huang Z, Samal SK (2003) Deduced amino acid
sequence of the small hydrophobic protein of US avian pneumovirus has greater
identity with that of human metapneumovirus than those of non-US avian
pneumoviruses. Virus Res 93: 91–97.
16. Whitehead SS, Bukreyev A, Teng MN, Firestone CY, St Claire M, et al. (1999)
Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or
SH gene is attenuated in chimpanzees. J Virol 73: 3438–3442.
17. Bukreyev A, Whitehead SS, Murphy BR, Collins PL (1997) Recombinant
respiratory syncytial virus from which the entire SH gene has been deleted grows
efficiently in cell culture and exhibits site-specific attenuation in the respiratory
tract of the mouse. J Virol 71: 8973–8982.
18. Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, et al. (2005)
Infection of nonhuman primates with recombinant human metapneumovirus
lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory
protein and identifies vaccine candidates. J Virol 79: 12608–12613.
19. Perez M, Garcia-Barreno B, Melero JA, Carrasco L, Guinea R (1997)
Membrane permeability changes induced in Escherichia coli by the SH protein
of human respiratory syncytial virus. Virology 235: 342–351.
20. Gan SW, Tan E, Lin X, Yu D, Wang J, et al. (2012) The small hydrophobic
protein of the human respiratory syncytial virus forms pentameric ion channels.
J Biol Chem.
21. Wilson RL, Fuentes SM, Wang P, Taddeo EC, Klatt A, et al. (2006) Function of
small hydrophobic proteins of paramyxovirus. J Virol 80: 1700–1709.
22. Fuentes S, Tran KC, Luthra P, Teng MN, He B (2007) Function of the
respiratory syncytial virus small hydrophobic protein. J Virol 81: 8361–8366.
23. Lin Y, Bright AC, Rothermel TA, He B (2003) Induction of apoptosis by
paramyxovirus simian virus 5 lacking a small hydrophobic gene. J Virol 77:
3371–3383.
24. He B, Lin GY, Durbin JE, Durbin RK, Lamb RA (2001) The SH integral
membrane protein of the paramyxovirus simian virus 5 is required to block
apoptosis in MDBK cells. J Virol 75: 4068–4079.
25. de Graaf M, Herfst S, Schrauwen EJ, van den Hoogen BG, Osterhaus AD, et al.
(2007) An improved plaque reduction virus neutralization assay for human
metapneumovirus. J Virol Methods 143: 169–174.
26. Kuiken T, Van Den Hoogen BG, Van Riel DA, Laman JD, Van Amerongen G,
et al. (2004) Experimental Human Metapneumovirus Infection of Cynomolgus
Macaques (Macaca fascicularis) Results in Virus Replication in Ciliated
Epithelial Cells and Pneumocytes with Associated Lesions throughout the
Respiratory Tract. Am J Pathol 164: 1893–1900.
27. van Wetering S, Zuyderduyn S, Ninaber DK, van Sterkenburg MA, Rabe KF,
et al. (2007) Epithelial differentiation is a determinant in the production of
eotaxin-2 and -3 by bronchial epithelial cells in response to IL-4 and IL-13. Mol
Immunol 44: 803–811.
28. Jin H, Zhou H, Cheng X, Tang R, Munoz M, et al. (2000) Recombinant
respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2
genes are attenuated in vitro and in vivo. Virology 273: 210–218.
29. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ (2002) Respiratory
syncytial virus infection of human airway epithelial cells is polarized, specific to
ciliated cells, and without obvious cytopathology. J Virol 76: 5654–5666.
30. Bao X, Sinha M, Liu T, Hong C, Luxon BA, et al. (2008) Identification of
human metapneumovirus-induced gene networks in airway epithelial cells by
microarray analysis. Virology 374: 114–127.
31. Brasier AR, Jamaluddin M, Casola A, Duan W, Shen Q, et al. (1998) A
promoter recruitment mechanism for tumor necrosis factor-alpha-induced
interleukin-8 transcription in type II pulmonary epithelial cells. Dependence
on nuclear abundance of Rel A, NF-kappaB1, and c-Rel transcription factors. J
Biol Chem 273: 3551–3561.
32. Garofalo R, Sabry M, Jamaluddin M, Yu RK, Casola A, et al. (1996)
Transcriptional activation of the interleukin-8 gene by respiratory syncytial virus
infection in alveolar epithelial cells: nuclear translocation of the RelA
transcription factor as a mechanism producing airway mucosal inflammation.
J Virol 70: 8773–8781.
33. Skiba M, Mettenleiter TC, Karger A (2008) Quantitative whole-cell proteome
analysis of pseudorabies virus-infected cells. J Virol 82: 9689–9699.
34. Biacchesi S, Murphy BR, Collins PL, Buchholz UJ (2007) Frequent frameshift
and point mutations in the SH gene of human metapneumovirus passaged in
vitro. J Virol 81: 6057–6067.
35. Herfst S, de Graaf M, Schrauwen EJ, Sprong L, Hussain K, et al. (2008)
Generation of temperature-sensitive human metapneumovirus strains that
provide protective immunity in hamsters. J Gen Virol 89: 1553–1562.
36. Buchholz UJ, Finke S, Conzelmann KK (1999) Generation of bovine respiratory
syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus
replication in tissue culture, and the human RSV leader region acts as a
functional BRSV genome promoter. J Virol 73: 251–259.
37. Reed LJ, Muench H (1938) A simple method of estimating fifty percent end
points. J Hyg 27: 493–497.
38. Pear WS, Nolan GP, Scott ML, Baltimore D (1993) Production of high-titer
helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90:
8392–8396.
39. Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P, et al. (2005) Parts per
million mass accuracy on an Orbitrap mass spectrometer via lock mass injection
into a C-trap. Mol Cell Proteomics 4: 2010–2021.
40. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy--analysis of Affymetrix
GeneChip data at the probe level. Bioinformatics 20: 307–315.
41. Smyth GK (2004) Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:
Article3.
42. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: a
Practical and Powerful Approach to Multiple Testing. J R Statist Soc B 51: 289–
300.
43. Dekker LJ, Burgers PC, Guzel C, Luider TM (2007) FTMS and TOF/TOF
mass spectrometry in concert: identifying peptides with high reliability using
matrix prespotted MALDI target plates. J Chromatogr B Analyt Technol
Biomed Life Sci 847: 62–64.
44. Mustafa DA, Burgers PC, Dekker LJ, Charif H, Titulaer MK, et al. (2007)
Identification of glioma neovascularization-related proteins by using MALDI-
FTMS and nano-LC fractionation to microdissected tumor vessels. Mol Cell
Proteomics 6: 1147–1157.
45. Titulaer MK, Siccama I, Dekker LJ, van Rijswijk AL, Heeren RM, et al. (2006)
A database application for pre-processing, storage and comparison of mass
spectra derived from patients and controls. BMC Bioinformatics 7: 403.
Function of HMPV SH Protein
PLOS ONE | www.plosone.org 10 March 2013 | Volume 8 | Issue 3 | e58572
